Navigation Links
ChanTest Awarded $1 Million Grant for Predictive Assays using Stem Cell-Derived Human Cardiomyocytes
Date:9/17/2012

CLEVELAND, Sept. 17, 2012 /PRNewswire/ -- ChanTest, the leading CRO expert in ion channels and nonclinical cardiac safety testing, announces funding of a Phase II SBIR grant.  ChanTest will use the grant from the National Heart Lung & Blood Institute to optimize drug safety and discovery assays using stem cell-derived human cardiomyocytes. 

(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )

"This grant will allow us to optimize our industry-leading cardiomyocyte assays," said ChanTest's Principal Investigator Andrew Bruening-Wright, Ph.D.   "With our collaborators at FDA, DSEC, and Leadscope, Inc., we have improved predictivity models based on currently available ChanTest services.  Our nonclinical models will only get better as we fully integrate cardiomyocyte-based assays." 

These cardiomyocyte assays are critical for improving the predictivity of nonclinical testing and reducing the use of animals as proposed in the NIH roadmap for drug discovery and the FDA's critical path initiative.  The grant will also fund development of automated instrument-based services to increase throughput and drive down costs to meet the needs of ChanTest customers.

Dr. Arthur "Buzz" Brown, founder and CEO of ChanTest and co-PI on the grant, added "ChanTest has assembled an expert team to ensure success of this grant. We'll build on this success to improve drug discovery for other diseases in which ion channels play a critical role."

About ChanTest – The Ion Channel Expert

ChanTest's mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company's library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest's seminal role in the nonclinical cardiac safety field, along with the company's uncompromising commitment to quality, ChanTest has been named the "most trusted and most used fee-for-service provider" for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.

 

CONTACT: Chris Mathes, +1-732-586-1073

 


'/>"/>
SOURCE ChanTest
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ChanTest hires Chris Mathes as Chief Commercial Officer
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. QBC Diagnostics Awarded GSA Contract
4. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
5. Northwest Bio Awarded $5.5 Million German Government Grant
6. Nonin Medical Awarded Novation Contract for Clinically Proven Pulse Oximeters
7. Elsevier / Gold Standards Kay Morgan Awarded NCPCP Highest Honor
8. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
9. New Chronic Wound Therapy Awarded at Texas Largest Life Science Event
10. SurgiCount Medical Awarded Contract From HealthTrust Purchasing Group for the Safety-Sponge® System
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... , Dec. 6, 2016 Two new disaster ... in a simulated mass casualty event Tuesday at John ... The technology debuted before an audience including ... representatives from Homeland Security, Federal Law Enforcement Agencies, and ... known as HiRO (Health Integrated Rescue Operations), was developed ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a worldwide ... US market its advanced highly customizable contact technology solutions. , ODU Single Contact ... technologies are ideal for a wide range of applications that require customization from ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance Agency, ... in the Sacramento/Folsom region, is initiating a charity event to raise support and ... Another Chance treatment center in Sacramento works to provide area teens and families ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from ... securement tape is painful for her. "This is why the co-inventor and I have ... said. , They then created a prototype of the patent-pending AV-AIR, a device that ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
Breaking Medicine News(10 mins):